Better Detection of Hepatitis B Virus After Treatment
Part of Digestive system, Infections clinical trials.
This study looks at a new way to detect the hepatitis B virus in the blood, even after standard tests say it's gone. It may help people who have stopped treatment and want to see if the virus comes back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You tested negative for hepatitis B surface antigen (HBsAg) using a standard test.
- You also tested negative for hepatitis B e antigen (HBeAg).
- You have stored blood samples taken before starting treatment and 48 weeks after stopping treatment.
- You are willing to come back for regular checkups for one year.
- You do not have liver cirrhosis, other liver diseases, or liver cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with hepatitis B (HBV) blood tests that have improved over the last year. It aims to learn what happens after the hepatitis B surface antigen (HBsAg) goes down, and may help doctors better predict outcomes.
This study tests a new antibody treatment (VIR-3434) for chronic hepatitis B. It aims to see if the antibody can help your immune system control the virus, potentially allowing you to stop your current antiviral medication later.
This study looks at how to best use existing hepatitis B “nucleotide-analog” tablets in everyday care. It may help tailor when to start, and whether to continue or adjust treatment, based on your test results.
This trial studies whether pegylated interferon can help people with inactive chronic hepatitis B stay stable or improve outcomes. You may qualify if your virus levels and liver blood tests are currently low and you’ve never used antiviral treatments.
This trial studies what happens to people with hepatitis B who have hepatitis B surface antigen for more than 6 months, are “HBeAg-negative,” and have certain blood and liver-scarring levels despite normal or near-normal liver inflammation. It may help doctors understand the best care for this specific group before clear treatment phases.
This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.
Hear when a new Hepatitis B, Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.